Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity [PDF]
, 2011 Vår uppsats handlar om formativ bedömning och vad det innebär att arbeta så i undervisningen. Vi tolkar att rådande läroplaner beskriver ett uppdrag som ligger i linje med ett formativt arbetssätt.
Sung-Jun Ko +12 more
core +1 more source
Cancer Science, EarlyView.The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada +9 more
wiley +1 more source
ALK rearrangement in a selected population of advanced non small cell lung cancer patients. FISH and inmunohistochemistry diagnostic methods, prevalence and clinical outcomes [PDF]
, 2012 Anaplastic lymphoma kinase (ALK) rearrangements represents a new driver oncogenic event in non-small cell lung cancer (NSCLC). ALK positive patients account for a 1-7% of NSCLC patients.
Felip, Enriqueta +4 more
core
Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer [PDF]
, 2018 Lung cancer is the leading cause of death worldwide. The treatment choice for advanced stage of lung cancer may depend on histotype, performance status (PS), age, and comorbidities. In the present study, we focused on the effect of metronomic vinorelbine
Bruno, P +7 more
core +1 more source
Jurnal RespirasiIntroduction: Lung cancer is a malignancy of the lung parenchyma or bronchi. Molecular targeted therapy directed at oncogene driver mutations, such as anaplastic lymphoma kinase (ALK), improves the prognosis of patients with non-small cell lung carcinoma
Muhammad Yusuf Adira Putra +6 more
doaj +1 more source
ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma
Diagnostic Pathology, 2019 Background Ovarian metastatic tumors from lung adenocarcinoma are rare, and a serial study of these tumors is lacking to date. Additionally, a better understanding of the clinicopathological and molecular characteristics of metastatic tumors is needed ...
Rui Bi +13 more
doaj +1 more source
Cancer Science, EarlyView.ABSTRACT In the randomized phase III CheckMate 77T study, perioperative nivolumab showed statistically significant and clinically meaningful improvement in event‐free survival (EFS) vs. placebo in patients with resectable, non‐metastatic non‐small cell lung cancer (NSCLC).
Fumihiro Tanaka +17 more
wiley +1 more source
Routine molecular profiling of cancer: results of a one-year nationwide program of the French Cooperative Thoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. [PDF]
, 2016 International audienceBackground: The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care.
Audigier-Valette, Clarisse +31 more
core +5 more sources
Cancer Science, EarlyView.The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori +12 more
wiley +1 more source
Targeted genomic rearrangements using CRISPR/Cas technology [PDF]
, 2014 Genomic rearrangements are frequently observed in cancer cells but have been difficult to generate in a highly specific manner for functional analysis.
Choi, Peter S., Meyerson, Matthew
core +1 more source